# A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

> **NCT05369403** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 86 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Lebrikizumab

## Key facts

- **NCT ID:** NCT05369403
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-19
- **Primary completion:** 2024-01-11
- **Final completion:** 2025-02-05
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369403, "A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05369403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*